Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Medical cannabis company Northern Leaf eyes London listing later this year

Published 12/02/2021, 07:00 pm
Updated 12/02/2021, 07:06 pm
© Reuters.
GWPH
-
RGT
-

Feb 12 (Reuters) - Northern Leaf Ltd is close to hiring a lead broker for a London stock listing later this year, its financial adviser said, a month after it became only the second company to receive a license for growing medical cannabis in the British Isles.

The Jersey-based company, preparing to grow cannabis in a 75,000 square feet greenhouse on the island, is currently raising 5 million pounds ($6.91 million) in private funding before the initial public offering, its adviser Tristan Gervais told Reuters.

Surging demand for medical cannabis, increasingly used to cope with mental health conditions such as depression, anxiety and insomnia, has pushed countries across Europe to consider tweaking their laws.

Britain last year paved the way for medical cannabis companies to list on the London Stock Exchange (LSE), sparking a race between firms to go public and raise money.

Australia's MGC Pharmaceuticals Ltd MXC.AX became the first medical cannabis company to trade on the LSE on Feb. 9, with its shares more than trebling since the debut.

"The UK Capital Markets are now open for strong medical cannabis businesses with appropriate UK licenses," said Gervais, who heads cannabis advisory at merchant bank Chrystal Capital.

Northern Leaf expects its first commercial harvest in the third quarter and can produce 6,500 kilograms of dry flower at full capacity. The company plans to sell its harvest in countries including the United Kingdom, Israel and Germany.

It plans to use the proceeds from its IPO to expand cultivation, install an extraction facility and build its own medical brands, Gervais said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Northern Leaf received its license nearly 22 years after GW Pharmaceuticals GWPH.O became the first company to win British approval to grow medical marijuana in the country. ($1 = 0.7240 pounds)

<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ Canadian pot producers may scale back in Europe - industry report

Once down in the weeds, cash-strapped pot producers raise billions in market rally

Cannabis stocks light up Reddit as sector surges to new highs

Jazz Pharma to buy GW Pharma for $7.2 bln, adding cannabis-based drug to portfolio

Regulatory jujitsu turns CBD into $7 bln deal

European medical marijuana sales set to rise

https://tmsnrt.rs/3tPyGaV

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.